Search

everythinglearnresearchcommunity

for

Search:↓

A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.

The user switched from topical to oral finasteride and minoxidil pills for hair loss but hasn't seen results after 4 months. Others suggest it may take longer to see improvements and recommend considering additional treatments.

The user experienced hair regrowth and thicker hair after using finasteride daily for four years and recently added topical minoxidil. They are considering derma stamping but are cautious about switching to dutasteride due to potential side effects.

The user experienced hair loss and started using minoxidil (5%) and finasteride (0.5 mg daily) with inconsistent application but still saw noticeable improvements by the end of January. They use the liquid form of minoxidil.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

A user experienced significant hair regrowth using finasteride and minoxidil over four years, despite side effects like seborrheic dermatitis, urinary changes, and water retention. They were satisfied with the results and maintained a strong physique.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

User shares 4-month hairline progress using minoxidil, finasteride, nizoral, and dermarolling. Others discuss treatment details and express admiration for the results.

User follows a hair loss protocol with topical finasteride, minoxidil, RU58841, stemoxydine, and microneedling. They plan to get a hair transplant at month 9 and ask for opinions on their progress.

The user shared their 4-year hair regrowth progress using finasteride, minoxidil, estradiol, and spironolactone. They noted significant regrowth by the second year and additional benefits from estradiol and spironolactone.

A 20-year-old has seen positive results for hair loss after 4 months using 1 mg finasteride daily, minoxidil twice daily, and weekly dermastamping with a 1.5 mm needle. They also used ketoconazole shampoo initially and recommend starting treatment early.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

The user shared progress after 4 months of using topical minoxidil daily, along with dermastamping and Nizoral shampoo. They are seeking suggestions for better results.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.

At 4 months post hair transplant, the user is taking oral minoxidil and finasteride, and progress is on track. Users suggest the results are good, with some recommending patience and others offering hair care advice.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.

The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.

The conversation is about hair loss treatment using finasteride, ketoconazole, and sulfur soap, with consideration of starting dermastamp. The user prefers not to use minoxidil.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user reported noticeable hair improvement over four months using 1 mg of finasteride and weekly microneedling. Progress photos from October 2024 to January 2025 show positive changes.

Hair loss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.